


**Amendments to the Claims**


*This listing of the claims will replace all prior listings or versions of the claims in the application:*

**Listing of Claims**

1. (Currently Amended) A method of treating a solid tumour in a subject, the method comprising the following steps
  - (i) delivering to the solid tumour
    - (a) ~~a composition comprising an engineered ovine atadenovirus comprising a probain promoter and a transcriptional enhancer sequence (PSME) operatively linked to a nucleotide sequence encoding a purine nucleoside phosphorylase (PND) enzyme, and~~
    - (b) ~~a CS87 lipid having the formula~~



or a CS60 lipid having the formula:



and

- (ii) administering a prodrug 6-methyl purine-2-deoxyriboside (6MPDR) or fludarabine to the subject to the subject,  
~~wherein the engineered ovine atadenovirus comprises a promoter and a gene encoding an enzyme which converts the prodrug to a cytotoxic metabolite, the gene being under the control of the promoter.~~

2. (Canceled)


3. (Previously Presented) A method as claimed in claim 1 in which the solid tumour is prostate cancer.

Claims 4- 28. (Canceled)


29. (New) A composition comprising:

- (i) an engineered ovine atadenovirus comprising a probasin promoter and a transcriptional enhancer sequence (PSME) operatively linked to a gene encoding a purine nucleoside phosphorylase (PNP) enzyme; and

(ii) a CS87 lipid having the formula:



or a CS60 lipid having the formula:



30. (New) A composition as claimed in claim 29, further comprising 6-methyl purine-  
xyriboside (6MPDR) or fludarabine